Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
In mice single-cell RNA sequencing identified a subpopulation of GLP-1R-positive memory T-cells that was mainly composed of exhausted CD8+ T cells: functionally, stimulation of the GLP-1R on these cells was found to mediate apoptosis and anergic signals, thereby suppressing effector T-cell function and the inflammatory response (49, 50)
Eli Lilly announced Phase 3 ATTAIN-1 trial results for orforglipron, an oral GLP-1 receptor agonist, showing significant weight loss in adults with obesity or overweight without diabetes
For in-vitro research planning only
Around half of this would still have been fine
Dosing protocol unless otherwise specified by your doctor is 0.2 ml sub-Q (300mcg) at bedtime five nights a week
Briefly, SURMOUNT-5 was a phase 3b multicenter, randomized, parallel-arm, open-label, active-controlled, 72-week trial that included adults aged 18 years or older, with a body mass index (BMI) 30 kg/m 2 or a BMI 27 kg/m 2 with at least one obesity-related complication (ORC, i.e., hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease), and relatively stable weight, not more than 5 kg change in 3 months before screening
US$ 28.91
US$ 22.72
US$ 27.75
US$ 25.84
